Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  Mesoblast Limited    MSB   AU000000MSB8

MESOBLAST LIMITED

(MSB)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/23
3.16 AUD   -0.94%
12:45aMESOBLAST : Annual Report to shareholders
PU
12:45aMESOBLAST : Notice of Annual General Meeting and Proxy Form
PU
12:20aMESOBLAST : Appendix 4G and Corporate Governance Statement
PU
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
3.23 3.4 3.25 3.19 3.16 Last
6483527 7558694 6209799 4050374 2667042 Volume
+3.86% +5.26% -4.41% -1.85% -0.94% Change
Financials
Sales 2021 159 M 113 M 113 M
Net income 2021 -48,4 M -34,4 M -34,4 M
Net cash position 2021 44,4 M 31,6 M 31,6 M
P/E ratio 2021 -44,9x
Yield 2021 -
Sales 2022 259 M 184 M 184 M
Net income 2022 25,5 M 18,1 M 18,1 M
Net Debt 2022 17,1 M 12,2 M 12,2 M
P/E ratio 2022 38,5x
Yield 2022 -
Capitalization 1 843 M 1 310 M 1 311 M
EV / Sales 2021 11,3x
EV / Sales 2022 7,18x
Nbr of Employees 102
Free-Float 77,7%
More Financials
Company
Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL... 
More about the company
Notations Surperformance© of Mesoblast Limited
Trading Rating : Investor Rating :
More Ratings
All news about MESOBLAST LIMITED
12:45aMESOBLAST : Annual Report to shareholders
PU
12:45aMESOBLAST : Notice of Annual General Meeting and Proxy Form
PU
12:20aMESOBLAST : Appendix 4G and Corporate Governance Statement
PU
10/22MESOBLAST : CytoDyn Appoints Mahboob Rahman, M.D., Ph.D., as Chief Scientific Of..
AQ
10/22MESOBLAST : Randomized Controlled Study Using Direct Injection of Remestemcel-L ..
AQ
10/22Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Infl..
GL
10/21MESOBLAST : Remestemcel Controlled Study in Crohns & Ulcerative Colitis
PU
10/21Australia shares rise on lift from financial, energy stocks
RE
10/20MESO INVESTOR ALERT : Bronstein, Gewirtz & Grossman, LLC Notifies Mesoblast Limi..
BU
10/19DEADLINE REMINDER : The Law Offices of Howard G. Smith Reminds Investors of Loom..
BU
10/16MESOBLAST : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Mesoblast Limited Investors ..
BU
10/15MESOBLAST : ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Acti..
BU
10/15GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class..
BU
10/14MESOBLAST LIMITED : - Randomized Controlled Phase 3 Trial of Remestemcel-L for R..
AQ
10/14MESOBLAST : Notice of Lead Plaintiff Deadline for Shareholders in the Mesoblast ..
BU
More news
News in other languages on MESOBLAST LIMITED
08/27MESOBLAST LIMITED : Veröffentlichung des Jahresergebnisses
08/27MESOBLAST LIMITED : publication des résultats annuels
More news
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 7,27 AUD
Last Close Price 3,16 AUD
Spread / Highest target 434%
Spread / Average Target 130%
Spread / Lowest Target -49,2%
EPS Revisions
Managers
NameTitle
Silviu Itescu Chief Executive Officer, MD & Executive Director
Joseph R. Swedish Independent Non-Executive Chairman
Dagmar Rosa-Bjorkeson Chief Operating Officer
Joshua Muntner Chief Financial Officer
Paul Simmons Head-Research & New Product Development
Sector and Competitors
1st jan.Capitalization (M$)
MESOBLAST LIMITED51.92%1 310
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830